Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 181 to 188 of 188 entries
Sorted by: Best Match Show Resources per page
Competing sexual-asexual generic names of .

IMA fungus

Healy R, Pfister DH, Rossman AY, Marvanová L, Hansen K.
PMID: 27990335
IMA Fungus. 2016 Dec;7(2):285-288. doi: 10.5598/imafungus.2016.07.02.08. Epub 2016 Nov 23.

Following the change that eliminated dual naming of sexual and asexual morphs of fungi, generic names of

Cite
Healy R, Pfister DH, Rossman AY, et al. Competing sexual-asexual generic names of . IMA Fungus. 2016;7(2):285-288doi: 10.5598/imafungus.2016.07.02.08.
Healy, R., Pfister, D. H., Rossman, A. Y., Marvanová, L., & Hansen, K. (2016). Competing sexual-asexual generic names of . IMA fungus, 7(2), 285-288. https://doi.org/10.5598/imafungus.2016.07.02.08
Healy, Roseanne, et al. "Competing sexual-asexual generic names of ." IMA fungus vol. 7,2 (2016): 285-288. doi: https://doi.org/10.5598/imafungus.2016.07.02.08
Healy R, Pfister DH, Rossman AY, Marvanová L, Hansen K. Competing sexual-asexual generic names of . IMA Fungus. 2016 Dec;7(2):285-288. doi: 10.5598/imafungus.2016.07.02.08. Epub 2016 Nov 23. PMID: 27990335; PMCID: PMC5159599.
Copy Download .nbib Format: NLM
Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes.

Journal of clinical medicine

Haensli C, Pfister IB, Garweg JG.
PMID: 34204266
J Clin Med. 2021 Jun 17;10(12). doi: 10.3390/jcm10122666.

No abstract available.

Cite
Haensli C, Pfister IB, Garweg JG. Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. J Clin Med. 2021;10(12)doi: 10.3390/jcm10122666.
Haensli, C., Pfister, I. B., & Garweg, J. G. (2021). Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. Journal of clinical medicine, 10(12), . https://doi.org/10.3390/jcm10122666
Haensli, Christof, et al. "Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes." Journal of clinical medicine vol. 10,12 (2021). doi: https://doi.org/10.3390/jcm10122666
Haensli C, Pfister IB, Garweg JG. Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. J Clin Med. 2021 Jun 17;10(12). doi: 10.3390/jcm10122666. PMID: 34204266; PMCID: PMC8235134.
Copy Download .nbib Format: NLM
Sareomycetes: more diverse than meets the eye.

IMA fungus

Mitchell JK, Garrido-Benavent I, Quijada L, Pfister DH.
PMID: 33726866
IMA Fungus. 2021 Mar 16;12(1):6. doi: 10.1186/s43008-021-00056-0.

Since its resurrection, the resinicolous discomycete genus Sarea has been accepted as containing two species, one with black apothecia and pycnidia, and one with orange. We investigate this hypothesis using three ribosomal (nuITS, nuLSU, mtSSU) regions from and morphological...

Cite
Mitchell JK, Garrido-Benavent I, Quijada L, et al. Sareomycetes: more diverse than meets the eye. IMA Fungus. 2021;12(1):6doi: 10.1186/s43008-021-00056-0.
Mitchell, J. K., Garrido-Benavent, I., Quijada, L., & Pfister, D. H. (2021). Sareomycetes: more diverse than meets the eye. IMA fungus, 12(1), 6. https://doi.org/10.1186/s43008-021-00056-0
Mitchell, James K, et al. "Sareomycetes: more diverse than meets the eye." IMA fungus vol. 12,1 (2021): 6. doi: https://doi.org/10.1186/s43008-021-00056-0
Mitchell JK, Garrido-Benavent I, Quijada L, Pfister DH. Sareomycetes: more diverse than meets the eye. IMA Fungus. 2021 Mar 16;12(1):6. doi: 10.1186/s43008-021-00056-0. PMID: 33726866; PMCID: PMC7961326.
Copy Download .nbib Format: NLM
Wanted on .

Fungal systematics and evolution

Ribes MA, Escobio V, Negrín R, Baral HO, Pfister DH, Quijada L.
PMID: 35005577
Fungal Syst Evol. 2021 Dec;8:129-142. doi: 10.3114/fuse.2021.08.10. Epub 2021 Nov 09.

No abstract available.

Cite
Ribes MA, Escobio V, Negrín R, et al. Wanted on . Fungal Syst Evol. 2021;8:129-142doi: 10.3114/fuse.2021.08.10.
Ribes, M. A., Escobio, V., Negrín, R., Baral, H. O., Pfister, D. H., & Quijada, L. (2021). Wanted on . Fungal systematics and evolution, 8129-142. https://doi.org/10.3114/fuse.2021.08.10
Ribes, M A, et al. "Wanted on ." Fungal systematics and evolution vol. 8 (2021): 129-142. doi: https://doi.org/10.3114/fuse.2021.08.10
Ribes MA, Escobio V, Negrín R, Baral HO, Pfister DH, Quijada L. Wanted on . Fungal Syst Evol. 2021 Dec;8:129-142. doi: 10.3114/fuse.2021.08.10. Epub 2021 Nov 09. PMID: 35005577; PMCID: PMC8687061.
Copy Download .nbib Format: NLM
Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics.

Cellular and molecular gastroenterology and hepatology

Texler B, Zollner A, Reinstadler V, Reider SJ, Macheiner S, Jelusic B, Pfister A, Watschinger C, Przysiecki N, Tilg H, Oberacher H, Moschen AR.
PMID: 34624526
Cell Mol Gastroenterol Hepatol. 2021 Oct 06;13(2):383-404. doi: 10.1016/j.jcmgh.2021.09.004. Epub 2021 Oct 06.

OBJECTIVE: By interfering with multiple cytokines, human Janus kinase inhibitors (JAKis) are of growing importance in the treatment of malignant and inflammatory conditions. Although tofacitinib has demonstrated efficacy as the first-in-class JAKi in ulcerative colitis many aspects concerning its...

Cite
Texler B, Zollner A, Reinstadler V, et al. Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics. Cell Mol Gastroenterol Hepatol. 2021;13(2):383-404doi: 10.1016/j.jcmgh.2021.09.004.
Texler, B., Zollner, A., Reinstadler, V., Reider, S. J., Macheiner, S., Jelusic, B., Pfister, A., Watschinger, C., Przysiecki, N., Tilg, H., Oberacher, H., & Moschen, A. R. (2021). Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics. Cellular and molecular gastroenterology and hepatology, 13(2), 383-404. https://doi.org/10.1016/j.jcmgh.2021.09.004
Texler, Bernhard, et al. "Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics." Cellular and molecular gastroenterology and hepatology vol. 13,2 (2021): 383-404. doi: https://doi.org/10.1016/j.jcmgh.2021.09.004
Texler B, Zollner A, Reinstadler V, Reider SJ, Macheiner S, Jelusic B, Pfister A, Watschinger C, Przysiecki N, Tilg H, Oberacher H, Moschen AR. Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics. Cell Mol Gastroenterol Hepatol. 2021 Oct 06;13(2):383-404. doi: 10.1016/j.jcmgh.2021.09.004. Epub 2021 Oct 06. PMID: 34624526.
Copy Download .nbib Format: NLM
Consensus nomenclature for dyneins and associated assembly factors.

The Journal of cell biology

Braschi B, Omran H, Witman GB, Pazour GJ, Pfister KK, Bruford EA, King SM.
PMID: 35006274
J Cell Biol. 2022 Feb 07;221(2). doi: 10.1083/jcb.202109014. Epub 2022 Jan 10.

Dyneins are highly complex, multicomponent, microtubule-based molecular motors. These enzymes are responsible for numerous motile behaviors in cytoplasm, mediate retrograde intraflagellar transport (IFT), and power ciliary and flagellar motility. Variants in multiple genes encoding dyneins, outer dynein arm (ODA)...

Cite
Braschi B, Omran H, Witman GB, et al. Consensus nomenclature for dyneins and associated assembly factors. J Cell Biol. 2022;221(2)doi: 10.1083/jcb.202109014.
Braschi, B., Omran, H., Witman, G. B., Pazour, G. J., Pfister, K. K., Bruford, E. A., & King, S. M. (2022). Consensus nomenclature for dyneins and associated assembly factors. The Journal of cell biology, 221(2), . https://doi.org/10.1083/jcb.202109014
Braschi, Bryony, et al. "Consensus nomenclature for dyneins and associated assembly factors." The Journal of cell biology vol. 221,2 (2022). doi: https://doi.org/10.1083/jcb.202109014
Braschi B, Omran H, Witman GB, Pazour GJ, Pfister KK, Bruford EA, King SM. Consensus nomenclature for dyneins and associated assembly factors. J Cell Biol. 2022 Feb 07;221(2). doi: 10.1083/jcb.202109014. Epub 2022 Jan 10. PMID: 35006274.
Copy Download .nbib Format: NLM
Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations.

Scientific reports

Zandi S, Pfister IB, Garweg JG.
PMID: 34907233
Sci Rep. 2021 Dec 14;11(1):23989. doi: 10.1038/s41598-021-03294-9.

The specific changes linked to de novo development of postoperative PVR have remained elusive and were the object of the underlying study. Vitreous fluid (VF) was obtained at the beginning of vitrectomy from 65 eyes that underwent vitrectomy for...

Cite
Zandi S, Pfister IB, Garweg JG. Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations. Sci Rep. 2021;11(1):23989doi: 10.1038/s41598-021-03294-9.
Zandi, S., Pfister, I. B., & Garweg, J. G. (2021). Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations. Scientific reports, 11(1), 23989. https://doi.org/10.1038/s41598-021-03294-9
Zandi, Souska, et al. "Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations." Scientific reports vol. 11,1 (2021): 23989. doi: https://doi.org/10.1038/s41598-021-03294-9
Zandi S, Pfister IB, Garweg JG. Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations. Sci Rep. 2021 Dec 14;11(1):23989. doi: 10.1038/s41598-021-03294-9. PMID: 34907233; PMCID: PMC8671512.
Copy Download .nbib Format: NLM
Combinatorial immunotherapy induces tumor-infiltrating CD8.

Journal for immunotherapy of cancer

Van Braeckel-Budimir N, Dolina JS, Wei J, Wang X, Chen SH, Santiago P, Tu G, Micci L, Al-Khami AA, Pfister S, Ram S, Sundar P, Thomas G, Long H, Yang W, Potluri S, Salek-Ardakani S.
PMID: 34903555
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003614.

BACKGROUND: Programmed death (ligand) 1 (PD-(L)1) blockade and OX40/4-1BB costimulation have been separately evaluated in the clinic to elicit potent antitumor T cell responses. The precise mechanisms underlying single agent activity are incompletely understood. It also remains unclear if...

Cite
Van Braeckel-Budimir N, Dolina JS, Wei J, et al. Combinatorial immunotherapy induces tumor-infiltrating CD8. J Immunother Cancer. 2021;9(12)doi: 10.1136/jitc-2021-003614.
Van Braeckel-Budimir, N., Dolina, J. S., Wei, J., Wang, X., Chen, S. H., Santiago, P., Tu, G., Micci, L., Al-Khami, A. A., Pfister, S., Ram, S., Sundar, P., Thomas, G., Long, H., Yang, W., Potluri, S., & Salek-Ardakani, S. (2021). Combinatorial immunotherapy induces tumor-infiltrating CD8. Journal for immunotherapy of cancer, 9(12), . https://doi.org/10.1136/jitc-2021-003614
Van Braeckel-Budimir, Natalija, et al. "Combinatorial immunotherapy induces tumor-infiltrating CD8." Journal for immunotherapy of cancer vol. 9,12 (2021). doi: https://doi.org/10.1136/jitc-2021-003614
Van Braeckel-Budimir N, Dolina JS, Wei J, Wang X, Chen SH, Santiago P, Tu G, Micci L, Al-Khami AA, Pfister S, Ram S, Sundar P, Thomas G, Long H, Yang W, Potluri S, Salek-Ardakani S. Combinatorial immunotherapy induces tumor-infiltrating CD8. J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003614. PMID: 34903555.
Copy Download .nbib Format: NLM
Showing 181 to 188 of 188 entries